Personalized mRNA vaccine for melanoma cut risk of cancer’s return in late-stage trial

A new personalized mRNA vaccine for melanoma is being hailed by some oncologists as a major breakthrough after it reduced the risk of cancer recurrence and death by 42% compared with standard treatment in a late-stage clinical trial. Dr. Robert Vonderheide, director of Penn Medicine’s Abramson…